Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    June 2017
  1. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;82:92-102.
    PubMed     Text format     Abstract available


  2. EMILE JF, Julie C, Le Malicot K, Lepage C, et al
    Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Eur J Cancer. 2017;82:16-24.
    PubMed     Text format     Abstract available


  3. CARRATO A, Abad A, Massuti B, Gravalos C, et al
    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Eur J Cancer. 2017;81:191-202.
    PubMed     Text format     Abstract available


  4. YAMANO T, Yamauchi S, Kimura K, Babaya A, et al
    Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
    Eur J Cancer. 2017;81:90-101.
    PubMed     Text format     Abstract available


  5. THOMSEN M, Guren MG, Skovlund E, Glimelius B, et al
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
    Eur J Cancer. 2017;81:26-35.
    PubMed     Text format     Abstract available


    March 2017
  6. FROUWS MA, Rademaker E, Bastiaannet E, van Herk-Sukel MP, et al
    The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
    Eur J Cancer. 2017;77:24-30.
    PubMed     Text format     Abstract available


  7. BERGER MD, Yamauchi S, Cao S, Hanna DL, et al
    Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Eur J Cancer. 2017;77:13-20.
    PubMed     Text format     Abstract available


  8. HOLCH JW, Heinemann V
    Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients.
    Eur J Cancer. 2017;77:1-2.
    PubMed     Text format    


  9. KWAKMAN JJ, Simkens LH, Mol L, Kok WE, et al
    Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Eur J Cancer. 2017;76:93-99.
    PubMed     Text format     Abstract available


  10. DEL RIO M, Mollevi C, Bibeau F, Vie N, et al
    Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Eur J Cancer. 2017;76:68-75.
    PubMed     Text format     Abstract available


  11. TREASURE T, Williams NR
    Best available evidence related to clinical benefit of surgical resection in multimodality treatment of metastatic colorectal cancer indicates that a randomised controlled trial is warranted.
    Eur J Cancer. 2017;75:310-312.
    PubMed     Text format    


    February 2017
  12. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Text format     Abstract available


  13. FRANKEN MD, van Rooijen EM, May AM, Koffijberg H, et al
    Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Eur J Cancer. 2017;75:204-212.
    PubMed     Text format     Abstract available


  14. HUGEN N, Nagtegaal ID
    Distinct metastatic patterns in colorectal cancer patients based on primary tumour location.
    Eur J Cancer. 2017;75:3-4.
    PubMed     Text format    


  15. PAPAMICHAEL D, Aapro M
    Geriatric factors and outcomes in metastatic colorectal cancer.
    Eur J Cancer. 2017 Feb 10. pii: S0959-8049(16)32566.
    PubMed     Text format    


    January 2017
  16. MODEST DP, Neumann UP, Pratschke J
    FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Eur J Cancer. 2017 Jan 9. pii: S0959-8049(16)33085.
    PubMed     Text format    


  17. SARTORE-BIANCHI A, Pietrantonio F, Amatu A, Milione M, et al
    Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Eur J Cancer. 2017;71:43-50.
    PubMed     Text format     Abstract available


  18. 'T LAM-BOER J, van der Stok EP, Huiskens J, Verhoeven RH, et al
    Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands.
    Eur J Cancer. 2017;71:109-116.
    PubMed     Text format     Abstract available


    December 2016
  19. CREMOLINI C, Casagrande M, Loupakis F, Aprile G, et al
    Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2016 Dec 13. pii: S0959-8049(16)32534.
    PubMed     Text format     Abstract available


    November 2016
  20. HOLCH JW, Ricard I, Stintzing S, Modest DP, et al
    The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Eur J Cancer. 2016;70:87-98.
    PubMed     Text format     Abstract available


  21. DUCREUX M, Pignon JP
    Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
    Eur J Cancer. 2016;69:178-179.
    PubMed     Text format    


  22. APARICIO T, Gargot D, Teillet L, Maillard E, et al
    Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Eur J Cancer. 2016 Nov 5. pii: S0959-8049(16)32475.
    PubMed     Text format     Abstract available


  23. ROTTENBERG Y, Ratzon NZ, Cohen M, Hubert A, et al
    Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study.
    Eur J Cancer. 2016;69:70-76.
    PubMed     Text format     Abstract available


  24. GOEY KK, 't Lam-Boer J, de Wilt JH, Punt CJ, et al
    Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Eur J Cancer. 2016;69:166-177.
    PubMed     Text format     Abstract available


    October 2016
  25. BOUCHAHDA M, Boige V, Smith D, Karaboue A, et al
    Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Eur J Cancer. 2016;68:163-172.
    PubMed     Text format     Abstract available


  26. PRICE T, Kim TW, Li J, Cascinu S, et al
    Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Eur J Cancer. 2016;68:51-59.
    PubMed     Text format     Abstract available


  27. ZHAO Y, Fan D, Ru B, Cheng KW, et al
    6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Eur J Cancer. 2016;68:38-50.
    PubMed     Text format     Abstract available


    September 2016
  28. HEINEMANN V, Rivera F, O'Neil BH, Stintzing S, et al
    A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2016;67:11-20.
    PubMed     Text format     Abstract available


    August 2016
  29. MOL L, Ottevanger PB, Koopman M, Punt CJ, et al
    The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Eur J Cancer. 2016;66:138-143.
    PubMed     Text format     Abstract available


    July 2016
  30. CABALLERO-BANOS M, Benitez-Ribas D, Tabera J, Varea S, et al
    Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Eur J Cancer. 2016;64:167-174.
    PubMed     Text format     Abstract available


    June 2016
  31. BREUGOM AJ, Bastiaannet E, Boelens PG, Iversen LH, et al
    Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
    Eur J Cancer. 2016;63:110-117.
    PubMed     Text format     Abstract available


    May 2016
  32. BANDO H, Doi T, Muro K, Yasui H, et al
    A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Eur J Cancer. 2016;62:46-53.
    PubMed     Text format     Abstract available


  33. LOGANADANE G, Servagi-Vernat S, Schernberg A, Schlienger M, et al
    Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
    Eur J Cancer. 2016;58:83-9.
    PubMed     Text format     Abstract available


    March 2016
  34. MCLACHLAN SA, Fisher RJ, Zalcberg J, Solomon M, et al
    The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
    Eur J Cancer. 2016;55:15-26.
    PubMed     Text format     Abstract available


  35. HAAGENSEN EJ, Thomas HD, Mudd C, Tsonou E, et al
    Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Eur J Cancer. 2016;56:69-76.
    PubMed     Text format     Abstract available


    January 2016
  36. HELDER-WOOLDERINK JM, Blok EA, Vasen HF, Hollema H, et al
    Ovarian cancer in Lynch syndrome; a systematic review.
    Eur J Cancer. 2016;55:65-73.
    PubMed     Text format     Abstract available


  37. FORMICA V, Formica D, Formica G
    The 'death pace' in the CO.17 trial.
    Eur J Cancer. 2016;53:1-4.
    PubMed     Text format     Abstract available


  38. CASHIN PH, Mahteme H, Spang N, Syk I, et al
    Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    Eur J Cancer. 2016;53:155-62.
    PubMed     Text format     Abstract available


  39. NOREN A, Eriksson HG, Olsson LI
    Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.
    Eur J Cancer. 2016;53:105-14.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: